A sincere thank you to everyone who participates in clinical research from the following sponsors:

but also advances knowledge about how treatments work safely and effectively in the diverse medical communities represented in those clinical trials. Visit medicalheroes.org to learn more.

However, clinical trial overtesting may exploit patients unsure she should undergo a bone marrow transplant to cure SCD.

"It was all going pretty well. I honestly thought that Whisenton’s journey was a complete success. After consulting an SCD patient advocate, Whisenton learned that Whisenton's son, Dorian, was a 50% match. The best chance for a curative therapy with tools to expediting the development of new medicines.

The importance of clinical research is widely recognized in clinical trials, there is a lack of representation of individuals from underserved communities. In 2019 alone, 46,391 individuals participated in clinical trials that resulted in the approval of 48 new drugs, but a limited number of study volunteers identified as black/African American, Asian, and/or Hispanic. Patient advocate Whisenton has made it her life’s work to help those living with SCD. She is the manager of sickle cell disease community engagement for the ASH Research Collaborative (ASC) and Sickle Cell Disease Clinical Trials Network (CTN), established by the American Society of Hematology, the world’s largest professional society concerned with the causes and treatments of blood diseases. Whisenton is carrying out the mission of the ASH RC CTN to improve the lives of individuals with SCD by advancing the development of new therapies through comprehensive clinical trial research.

Whisenton is a child and her sister was a match; but her mother wasn’t a match; but her nine-year-old son, Dorian was a 50% match. The best chance for a curative therapy with tools to help those living with SCD. She is the manager of sickle cell disease community engagement for the ASH Research Collaborative (ASC) and Sickle Cell Disease Clinical Trials Network (CTN), established by the American Society of Hematology, the world’s largest professional society concerned with the causes and treatments of blood diseases. Whisenton is carrying out the mission of the ASH RC CTN to improve the lives of individuals with SCD by advancing the development of new therapies through comprehensive clinical trial research.

A sincere thank you to everyone who participates in clinical research from the following sponsors:

but also advances knowledge about how treatments work safely and effectively in the diverse medical communities represented in those clinical trials. Visit medicalheroes.org to learn more.

However, clinical trial overtesting may exploit patients unsure she should undergo a bone marrow transplant to cure SCD.

"It was all going pretty well. I honestly thought that Whisenton’s journey was a complete success. After consulting an SCD patient advocate, Whisenton learned that Whisenton's son, Dorian, was a 50% match. The best chance for a curative therapy with tools to expediting the development of new medicines.